GCG and type 2 diabetes mellitus: The two novel long-acting GLP-1 RAs offer patients who have type 2 diabetes the advantage to lower the glycaemic parameters HbA1c and fasting and postprandial blood glucose while having a low risk of hypoglycaemia as well as the possibility of losing body weight.